Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half effective dose of remimazolam in painless colonoscopy
ChiCTR2000040900Phase 4Recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam, sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoints: Half effective dose (ED50) of remimazolam for painless colonoscopy and 95% confidence limits for ED50. Started Jan 2021; status: recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2000040900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040900.